- Home
- XFOR vs INMB Comparison
XFOR vs INMB Comparison
Compare XFOR & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- INMB
- Stock Information
- Founded
- XFOR 2014
- INMB 2015
- Country
- XFOR United States
- INMB United States
- Employees
- XFOR N/A
- INMB N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- INMB Health Care
- Exchange
- XFOR Nasdaq
- INMB Nasdaq
- Market Cap
- XFOR 118.4M
- INMB 103.1M
- IPO Year
- XFOR N/A
- INMB 2019
- Fundamental
- Price
- XFOR $0.51
- INMB $6.45
- Analyst Decision
- XFOR Strong Buy
- INMB Strong Buy
- Analyst Count
- XFOR 3
- INMB 2
- Target Price
- XFOR $3.50
- INMB $21.00
- AVG Volume (30 Days)
- XFOR 2.9M
- INMB 377.7K
- Earning Date
- XFOR 11-13-2024
- INMB 10-31-2024
- Dividend Yield
- XFOR N/A
- INMB N/A
- EPS Growth
- XFOR N/A
- INMB N/A
- EPS
- XFOR N/A
- INMB N/A
- Revenue
- XFOR $1,123,000.00
- INMB $42,000.00
- Revenue This Year
- XFOR N/A
- INMB N/A
- Revenue Next Year
- XFOR $652.72
- INMB N/A
- P/E Ratio
- XFOR N/A
- INMB N/A
- Revenue Growth
- XFOR N/A
- INMB N/A
- 52 Week Low
- XFOR $0.26
- INMB $4.32
- 52 Week High
- XFOR $1.60
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- XFOR 42.67
- INMB 63.48
- Support Level
- XFOR $0.43
- INMB $5.82
- Resistance Level
- XFOR $0.89
- INMB $6.83
- Average True Range (ATR)
- XFOR 0.09
- INMB 0.55
- MACD
- XFOR -0.04
- INMB 0.18
- Stochastic Oscillator
- XFOR 17.61
- INMB 83.61
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.